Express Scripts Holding Co., a pharmacy benefit manager that handles more than 1 billion prescriptions annually in the U.S., is ratcheting up its effort to force Gilead Sciences Inc. to cut the $84,000 price of its new hepatitis C pill Sovaldi.
U.K. stocks snapped two days of gains as the European Central Bank left its key interest rate at a record low and President Mario Draghi said policy makers debated measures such as large-scale asset purchases.
The price of Gilead Sciences Inc.’s $1,000-a-day hepatitis C pill is keeping state-run Medicaid programs from making it available to many of the people who are most likely to be infected with the disease.
China Medical System Holdings Ltd. fell the most since listing in Hong Kong after the preliminary results of a clinical trial on a liver cancer treatment showed no statistical difference from a placebo in some patient groups.
Chinese stocks listed in Hong Kong fell to a three-week low as the national legislature began its annual meeting and concern mounted that the country may be facing its first onshore corporate bond default.